Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS-wild type lung adenocarcinoma reveals gene signatures associated with patient outcome.
In lung adenocarcinoma, EGFR and KRAS mutations dominate the mutational spectrum and have clear therapeutic implications. We sought to determine whether transcriptional subgroups of clinical relevance exist within EGFR-mutated, KRAS-mutated, or EGFR and KRAS-wild type (EGFRwt/KRASwt) adenocarcinomas.